Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Novel Epidemiological Approaches in Clinical Pharmacology and Toxicology
share announcement

Novel Epidemiological Approaches in Clinical Pharmacology and Toxicology

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 1013

Special Issue Editors

Dr. Niccolò Lombardi

E-Mail Website
Guest Editor
1. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, 50141 Florence, Italy
2. Tuscan Regional Centre of Pharmacovigilance, 50122 Florence, Italy
Interests: clinical pharmacology and toxicology; pharmacovigilance and pharmacoepidemiology
Special Issues, Collections and Topics in MDPI journals
Dr. Giada Crescioli

E-Mail Website
Guest Editor
1. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, 50141 Florence, Italy
2. Tuscan Regional Centre of Pharmacovigilance, 50122 Florence, Italy
Interests: clinical pharmacology and toxicology; pharmacovigilance and pharmacoepidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Novel epidemiological approaches in clinical pharmacology and toxicology aim to enhance our understanding of how drugs affect populations and individuals. These approaches utilize advanced methodologies, data sources, and analytical techniques to investigate the safety, efficacy, and toxicity of drugs. Some of the emerging trends and approaches in this field are represented by real-world data (RWD) and real-world evidence (RWE), Bayesian methods, network pharmacology, longitudinal data analysis, and machine learning and artificial intelligence (AI).

In recent years, novel epidemiological approaches have had a broad and far-reaching impact on clinical pharmacology, toxicology, epidemiology, and other fields.

We have launched a Special Issue, “Novel Epidemiological Approaches in Clinical Pharmacology and Toxicology”, and we encourage you and your colleagues to submit articles related to clinical pharmacology, toxicology, and epidemiology with a focus on new research methodologies. Original research articles and reviews are welcome.

Dr. Niccolò Lombardi
Dr. Giada Crescioli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical pharmacology
  • toxicology
  • epidemiology
  • the value of real-world evidence
  • adverse drug reactions
  • drug safety

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1022 KiB  
Article
Two Years of Active Pharmacovigilance Surveillance and Therapeutic Reconciliation in Frail Populations: The MEAP 3.0 Study
by Anna Bombelli, Greta Guarnieri, Niccolò Lombardi, Maria Giuseppa Sullo, Edoardo Spina, Giada Crescioli, Concetta Rafaniello, Giuseppe Cicala, Veronica Marangon, Rachele Folchino, Silvia Vecchio, Giulia Mosini, Sonia Radice, Emilio Clementi and MEAP 3.0 Group
J. Clin. Med. 2023, 12(23), 7447; https://doi.org/10.3390/jcm12237447 - 30 Nov 2023
Viewed by 818
Abstract
Awareness related to the risk/benefit profile of therapies used in paediatric and elderly patients is limited. We carried out a study, called the MEAP 3.0 study, to collect and analyse evidence of adverse drug reactions (ADRs) and drug–drug interactions (DDIs) that occurred in [...] Read more.
Awareness related to the risk/benefit profile of therapies used in paediatric and elderly patients is limited. We carried out a study, called the MEAP 3.0 study, to collect and analyse evidence of adverse drug reactions (ADRs) and drug–drug interactions (DDIs) that occurred in frail populations under polypharmacy in a real-world setting. Data were retrieved from reports of ADRs and pharmacological counselling from patients treated in hospitals and territorial health services. We collected 2977 ADRs reports and identified ‘anti-infectives for systemic use’ and ‘cardiovascular system’ as the most frequently implicated pharmacological classes in under-18 and over-65 patients, respectively. We detected 2179 DDIs, of which 10.7% were related to at least one ADR: 22 were classified as ‘contraindicated’ (7 in the paediatric group and 15 in the elderly one), and 61 as ‘major’ (6 in the paediatric patients and 55 in the geriatric ones), while 151 DDIs were classified as ‘moderate’ (10 referred to paediatric population, and 109 to elderly patient) and as ‘minor’ (1 in paediatric patients, and 31 in the elderly ones). The MEAP 3.0 project demonstrates that pharmacovigilance surveillance and therapeutic reconciliation are valid strategies to avoid potential DDIs and the occurrence of ADRs, allowing for personalised medicine. Full article
(This article belongs to the Special Issue Novel Epidemiological Approaches in Clinical Pharmacology and Toxicology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop